The following study was conducted by Scientists from Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Public Health Clinical Center, Fudan University, Shanghai, China; Active Motif China, Inc., Shanghai, China; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China; National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China; Zhejiang Hisun Pharmaceutical Co., Ltd., Taizhou City, Zhejiang Province, China; Shanghai Public Health Clinical Center, Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, China. Study is published in Cell Reports Journal – Cell Press Publishing as detailed below.
Cell Reports Journal – Cell Press Publishing (2020)
Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection
Highlights
- 11 neutralizing antibodies against SARS-CoV-2 target three main epitopes on RBD
- Epitope-A antibody 414-1 shows neutralizing IC50 at 1.75 nM
- Epitope-B antibody 553-15 can enhance the neutralizing abilities of other antibodies
- One neutralizing antibody, 515-5, can cross neutralize SARS-CoV pseudovirus
Summary
Coronavirus disease 2019 (COVID-19) has become a worldwide threat to humans, and neutralizing antibodies have therapeutic potential. We have purified more than 1,000 memory B cells specific to SARS-CoV-2 S1 or its RBD (receptor binding domain) and obtain 729 paired heavy- and light-chain fragments. Among these, 178 antibodies test positive for antigen binding, and the majority of the top 17 binders with EC50 below 1 nM are RBD binders. Furthermore, we identify 11 neutralizing antibodies, eight of which show IC50 within 10 nM, and the best one, 414-1, with IC50 of 1.75 nM. Through epitope mapping, we find three main epitopes in RBD recognized by these antibodies, and epitope-B antibody 553-15 could substantially enhance the neutralizing abilities of most of the other antibodies. We also find that 515-5 could cross neutralize the SARS-CoV pseudovirus. Altogether, our study provides 11 potent human neutralizing antibodies for COVID-19 as therapeutic candidates.
Source:
Cell Reports Journal – Cell Press Publishing
URL: https://www.cell.com/cell-reports/fulltext/S2211-1247(20)30899-8
Citation:
Wan, J., S. Xing, et al. (2020). “Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.” Cell Reports 32(3).
